SweetValueLab
Write for us

Viking Therapeutics, Inc. — Wall Street Analyst Estimates & Price Targets

VKTX
NASDAQHealthcareBiotechnologyCIK 0001607678vikingtherapeutics.comAbout VKTX
Quant grade ?D
Last close · Oct 30, 202627.28+0.42 (+1.56%)

The analysts at a glance

close of Oct 30, 2026
$85.00median of 3 firms' latest targets, 212% above the last close of $27.28
$85.0$34.0$120last close $27.3
Firms with a target · last 90 days
3
Lowest – highest target
$34.00 – $120.00
Current grades of 6 firms: positive / neutral / negative
6 / 0 / 0
Upgrades / downgrades · 12 months
0 / 0

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$25.0$50.0$75.0$100$125NovJan 2026MarMayJulSep2025-11-12 · Canaccord Genuity: $1072026-02-12 · Morgan Stanley: $99.02026-03-12 · Jefferies: $1012026-04-30 · Morgan Stanley: $95.02026-04-30 · Cantor Fitzgerald: $1002026-05-27 · Truist: $83.02026-05-28 · Lake Street: $89.02026-09-21 · Oppenheimer: $1002026-09-22 · Oppenheimer: $1202026-09-23 · Truist: $87.02026-10-07 · Truist: $85.02026-10-29 · Goldman Sachs: $34.0
$25.0$50.0$75.0$100$125NovFebMayAug

Each firm's latest target

last 90 days · 3 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-29Goldman Sachs$34.00——+34%+25%
2026-10-07Truist$85.00$87.00▼ 2%+195%+212%
2026-09-22Oppenheimer$120.00$100.00▲ 20%+211%+340%

Current grades

each firm's latest · 6 firms
As ofFirmGrade
2026-10-30Canaccord Genuity“Buy”
2026-10-07Truist“Buy”
2026-08-11J.P. Morgan“Overweight”
2026-05-01BTIG“Buy”
2026-04-30Cantor Fitzgerald“Overweight”
2026-03-23H.C. Wainwright“Buy”

Grade changes

last 24 months · 0
DateFirmGrade
None in the last 24 months.
4 older than 24 months
2024-05-16Raymond James“Outperform” → “Strong Buy” upgrade
2021-05-25Raymond James“Strong Buy” → “Outperform” downgrade
2019-03-29Leerink Partners“Market Perform” → “Outperform” upgrade
2018-11-19Raymond James“Outperform” → “Strong Buy” upgrade

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2020reported$0—-$0.50—est. $6.2M-100%est. -$0.5518
2025reported$0—-$3.19—est. $1.5M-100%est. -$2.7211
2026$7.2M—-$5.32—$7.2M–$7.2M-$6.38–-$4.549
2027$7.3M+3%-$5.15—$7.3M–$7.3M-$7.62–-$2.8110
2028$217.2M+2855%-$3.93—$207.6M–$226.7M-$6.62–$1.2215
2029$482.5M+122%-$1.69—$482.5M–$482.5M-$1.69–-$1.6910
2030$1.1B+138%$1.66—$1.1B–$1.1B$1.66–$1.667
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.